论文部分内容阅读
目的：观察脂必妥与普伐他汀治疗高脂血症的疗效。方法：６８例高脂血症病人分为脂必妥组３０例（男性１１例，女性１９例；年龄５９±ｓ１１ａ）和普伐他汀组３８例（男性１８例，女性２０例；年龄５６±９ａ）。分别用脂必妥１．０５ｇｐｏｂｉｄ×８ｗｋ和普伐他汀５ｍｇ，ｐｏｔｉｄ×８ｗｋ。结果：脂必妥组与普伐他汀组降ＴＣ总有效率分别为８８％，８９％；降ＴＧ总有效率分别为８０％，８２％；升高ＨＤＬ－ｃｈ为６５％，６８％；降动脉粥样硬化指数（ＡＩ）总有效率为８４％，８６％。组间比较Ｐ＞０．０５。结论：脂必妥与普伐他汀调脂效果均显著，但前者不良反应小于普伐他汀。
Objective: To observe the effect of Lipid and pravastatin in the treatment of hyperlipidemia. Methods: Sixty-eight patients with hyperlipidemia were divided into three groups: 30 patients (11 males, 19 females; age 59 ± s11a) and pravastatin group (18 males and 20 females; age 56 ± 9a). Respectively with Lipid 1.05gpobid × 8wk and pravastatin 5mg, potid × 8wk. Results: The total effective rate (TC) of lipid-lowering group and pravastatin group decreased by 88% and 89%, respectively. The total effective rate of lowering TG was 80% and 82% respectively. The increase of HDL-ch was 65% and 68% The total effective rate of atherosclerosis index (AI) was 84% and 86%. Comparison between groups P> 0.05. Conclusion: Lipid and pravastatin have significant effects on lipid regulation, but the former has less adverse reaction than pravastatin.